Related Experiment Videos
[Cardiac output and central-hemodynamic parameter under bencyclan (author's transl)]
Zeitschrift Fur Kardiologie
|January 1, 1979
Summary
Bencyclane (Fludilat) at 200 mg significantly decreased cardiac output and heart rate in peripheral arterial occlusive disease patients. Higher doses also increased aortic and pulmonary pressures, indicating potential negative inotropic effects requiring consideration during therapeutic use.
Area of Science:
- Cardiology
- Pharmacology
- Vascular Medicine
Background:
- Peripheral arterial occlusive disease (PAOD) affects circulation.
- Bencyclane (Fludilat) is used for circulatory disorders.
- Central hemodynamic effects of Bencyclane in PAOD patients require investigation.
Purpose of the Study:
- To investigate the influence of intravenous Bencyclane on cardiac output and central hemodynamic parameters in PAOD patients.
Main Methods:
- 17 patients with PAOD were administered intravenous Bencyclane.
- Two doses were tested: 100 mg (n=8) and 200 mg (n=9).
- Cardiac output, heart rate, aortic pressure, pulmonary arterial pressure, and pulmonary vessel resistance were measured.
Main Results:
- 100 mg Bencyclane had minimal effect on cardiac output.
- 200 mg Bencyclane significantly decreased cardiac output (-17.22%) and heart rate (-8.85%).
- Both doses significantly increased aortic pressure, pulmonary arterial pressure, and pulmonary vessel resistance.
Conclusions:
- Bencyclane exhibits dose-dependent effects on central hemodynamics in PAOD patients.
- The observed effects align with animal studies demonstrating negative inotropy.
- Clinical use of Bencyclane requires careful consideration of its impact on cardiac function and vascular resistance.